Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal STRING Test With Oral Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial~* Able to swallow the EST.~Exclusion Criteria: • Allergy to, or inability to ingest, gelatin~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- String Test-cohort A (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~A. Omalizumab for 8 weeks followed by mOIT with placebo for dupilumab for 24 weeks (Cohort A: Omalizumab-facilitated mOIT)
- String Test-cohort B (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~B. Omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort B: Omalizumab-facilitated mOIT with concurrent dupilumab)
- String Test-cohort C (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~C. Placebo for omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort C: mOIT with concurrent dupilumab)

Based on this trial design, predict the completion outcome and termination type (if applicable).